| Genotype . | Incidence . | Disease onset . | AUC . |
|---|---|---|---|
| Constitutive KO mice | |||
| WT | 22/22 (100%) | 12.6 ± 4.2 | 39 ± 4a |
| Il-1r1−/− | 7/13 (54%) | 25.0 ± 3.0 | 3 ± 2a |
| WT | 12/13 (92%) | 11.8 ± 0.6 | 60 ± 7 |
| Il-1α−/− | 15/15 (100%) | 12.2 ± 0.5 | 72 ± 7 |
| WT | 17/17 (100%) | 13.4 ± 0.9 | 69 ± 9b |
| Il-1β−/− | 10/29 (34%) | 31.7 ± 1.9 | 4.2 ± 2.3b |
| Bone marrow chimeric mice | |||
| WT → WT | 8/8 (100%) | 11.6 ± 0.4 | 89 ± 8 |
| Il-1r1−/− → WT | 7/7 (100%) | 12.0 ± 0.8 | 78 ± 11 |
| WT → Il-1r1−/− | 6/6 (100%) | 16.8 ± 1.4 | 52 ± 7 |
| Il-1r1−/− → Il-1r1−/− | 5/7 (71%) | 17.0 ± 0.5 | 19 ± 5 |
| WT → WT | 15/15 (100%) | 11.1 ± 0.4 | 79 ± 7 |
| Il-1α−/− → WT | 15/15 (100%) | 11.6 ± 0.4 | 72 ± 5 |
| WT → Il-1α−/− | 15/15 (100%) | 11.9 ± 0.2 | 83 ± 5 |
| Il-1α−/− → Il-1α−/− | 16/16 (100%) | 11.8 ± 0.4 | 85 ± 5 |
| WT → WT | 15/15 (100%) | 11.1 ± 0.4 | 79 ± 7 |
| Il-1β−/− → WT | 7/11 (64%) | 25.6 ± 3.0 | 9 ± 4 |
| WT → Il-1β−/− | 14/14 (100%) | 13.5 ± 0.8 | 66 ± 5 |
| Il-1β−/− → Il-1β−/− | 7/12 (58%) | 25.0 ± 2.0 | 15 ± 5 |
| Genotype . | Incidence . | Disease onset . | AUC . |
|---|---|---|---|
| Constitutive KO mice | |||
| WT | 22/22 (100%) | 12.6 ± 4.2 | 39 ± 4a |
| Il-1r1−/− | 7/13 (54%) | 25.0 ± 3.0 | 3 ± 2a |
| WT | 12/13 (92%) | 11.8 ± 0.6 | 60 ± 7 |
| Il-1α−/− | 15/15 (100%) | 12.2 ± 0.5 | 72 ± 7 |
| WT | 17/17 (100%) | 13.4 ± 0.9 | 69 ± 9b |
| Il-1β−/− | 10/29 (34%) | 31.7 ± 1.9 | 4.2 ± 2.3b |
| Bone marrow chimeric mice | |||
| WT → WT | 8/8 (100%) | 11.6 ± 0.4 | 89 ± 8 |
| Il-1r1−/− → WT | 7/7 (100%) | 12.0 ± 0.8 | 78 ± 11 |
| WT → Il-1r1−/− | 6/6 (100%) | 16.8 ± 1.4 | 52 ± 7 |
| Il-1r1−/− → Il-1r1−/− | 5/7 (71%) | 17.0 ± 0.5 | 19 ± 5 |
| WT → WT | 15/15 (100%) | 11.1 ± 0.4 | 79 ± 7 |
| Il-1α−/− → WT | 15/15 (100%) | 11.6 ± 0.4 | 72 ± 5 |
| WT → Il-1α−/− | 15/15 (100%) | 11.9 ± 0.2 | 83 ± 5 |
| Il-1α−/− → Il-1α−/− | 16/16 (100%) | 11.8 ± 0.4 | 85 ± 5 |
| WT → WT | 15/15 (100%) | 11.1 ± 0.4 | 79 ± 7 |
| Il-1β−/− → WT | 7/11 (64%) | 25.6 ± 3.0 | 9 ± 4 |
| WT → Il-1β−/− | 14/14 (100%) | 13.5 ± 0.8 | 66 ± 5 |
| Il-1β−/− → Il-1β−/− | 7/12 (58%) | 25.0 ± 2.0 | 15 ± 5 |
Two independent experiments were performed, and the pooled data are shown.
The area under the curve (AUC) was calculated up to day 28 after MOG35–55 immunization.
The AUC was calculated only for the first experiment (WT mice, n = 7; Il-1β−/− mice, n = 10), as mice included in the second experiment were killed at EAE onset + 1.